Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII

Haemophilia

Volumn 15, Issue 2, 2009, Pages 597-600

  Bajwa, Naghmana ^a   Enriquez, M M ^b   Gorina, E ^a   Lemm, G ^a  

^a BAYER CORPORATION   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE;

ARTICLE; BLEEDING DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; JOINT DESTRUCTION; POPULATION RISK; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SUCROSE GRADIENT;

FACTOR VIII; HEMOPHILIA A; HUMANS; SUCROSE; TREATMENT OUTCOME;

EID: 63349085895     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01938.x     Document Type: Article

References (5)

1. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
2. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
3. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
4. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
5. Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D. First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia 2002; 8: 776-80.